These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452 [TBL] [Abstract][Full Text] [Related]
4. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038 [TBL] [Abstract][Full Text] [Related]
5. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism. Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816 [TBL] [Abstract][Full Text] [Related]
6. Effect of a potent cyclooxygenase inhibitor, 5-ethyl-4-methoxy-2-phenylquinoline (KTC-5), on human platelets. Liao CH; Liao CH; Chang YL; Guh JH; Kuo SC; Huang LJ; Teng CM J Pharm Pharmacol; 2002 Jul; 54(7):967-74. PubMed ID: 12162716 [TBL] [Abstract][Full Text] [Related]
7. Mepacrine blockade of arachidonate-induced washed platelet aggregation: relationship to mepacrine inhibition of platelet cyclooxygenase. Raz A Thromb Haemost; 1983 Dec; 50(4):784-6. PubMed ID: 6420923 [TBL] [Abstract][Full Text] [Related]
8. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606 [TBL] [Abstract][Full Text] [Related]
9. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. Hornby EJ; Foster MR; McCabe PJ; Stratton LE Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661 [TBL] [Abstract][Full Text] [Related]
10. Isomers of trans fatty acids modify the activity of platelet 12-P lipoxygenase and cyclooxygenase/thromboxane synthase. Stachowska E; Dołegowska B; Olszewska M; Gutowska I; Chlubek D Nutrition; 2004 Jun; 20(6):570-1. PubMed ID: 15165621 [TBL] [Abstract][Full Text] [Related]
11. Effect of minoxidil on platelet function and the synthesis of prostaglandins in platelets. O'Barr TP; Swanson EW; Fitzpatrick JE; Corby DG J Lab Clin Med; 1989 Nov; 114(5):575-8. PubMed ID: 2553835 [TBL] [Abstract][Full Text] [Related]
12. Isolation and effects of some garlic components on platelet aggregation and metabolism of arachidonic acid in human blood platelets. Srivastava KC; Justesen U Wien Klin Wochenschr; 1989 Apr; 101(8):293-9. PubMed ID: 2499123 [TBL] [Abstract][Full Text] [Related]
13. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation. Nyby MD; Sasaki M; Ideguchi Y; Wynne HE; Hori MT; Berger ME; Golub MS; Brickman AS; Tuck ML J Pharmacol Exp Ther; 1996 Aug; 278(2):503-9. PubMed ID: 8768697 [TBL] [Abstract][Full Text] [Related]
14. Effects on primary haemostasis of an anti-inflammatory agent with 5-lipoxygenase and cyclooxygenase inhibitory activity. Hernandez MR; Tonda R; Pedreño J; Salas E; Arderiu G; Pino M; Serradell M; Escolar G J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):859-65. PubMed ID: 17122671 [TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894 [TBL] [Abstract][Full Text] [Related]
16. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Zimmermann N; Wenk A; Kim U; Kienzle P; Weber AA; Gams E; Schrör K; Hohlfeld T Circulation; 2003 Aug; 108(5):542-7. PubMed ID: 12874188 [TBL] [Abstract][Full Text] [Related]
17. Miconazole inhibition of platelet aggregation by inhibiting cyclooxygenase. Ishikawa S; Manabe S; Wada O Biochem Pharmacol; 1986 Jun; 35(11):1787-92. PubMed ID: 3087363 [TBL] [Abstract][Full Text] [Related]
18. A novel pyridobenzazepinone derivative with long lasting thromboxane synthase inhibition. Miki I; Kishibayashi N; Takeda M; Suzuki K; Obase H; Ishii A Arzneimittelforschung; 1995 Oct; 45(10):1066-70. PubMed ID: 8595060 [TBL] [Abstract][Full Text] [Related]
19. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910 [TBL] [Abstract][Full Text] [Related]
20. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro. De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]